AR127455A1 - Constructos de ácido nucleico, vectores víricos y partículas víricas - Google Patents

Constructos de ácido nucleico, vectores víricos y partículas víricas

Info

Publication number
AR127455A1
AR127455A1 ARP220102900A ARP220102900A AR127455A1 AR 127455 A1 AR127455 A1 AR 127455A1 AR P220102900 A ARP220102900 A AR P220102900A AR P220102900 A ARP220102900 A AR P220102900A AR 127455 A1 AR127455 A1 AR 127455A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
viral
acid construct
stxbp1
viral vector
Prior art date
Application number
ARP220102900A
Other languages
English (en)
Inventor
Brittany Nicole Vallette
Christian Gilbert Joseph Wolff
Alvarez Natalia Rodriguez
Meiyu Xu
Csilla Sipeky
Original Assignee
UCB Biopharma SRL
Ucb Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL, Ucb Biosciences Inc filed Critical UCB Biopharma SRL
Publication of AR127455A1 publication Critical patent/AR127455A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

La presente invención se refiere a un constructo de ácido nucleico que comprende un transgén que codifica la proteína de unión a la sintaxina 1 (STXBP1, Munc-18), un vector vírico para encapsidado de dicho ácido nucleico en una partícula vírica; y el uso de dicha partícula vírica para tratar una enfermedad asociada con una pérdida de la actividad funcional de STXBP1. Reivindicación 1: Un constructo de ácido nucleico que comprende un transgén caracterizado porque codifica: i. una proteína de unión a la sintaxina 1 (STXBP1) que comprende la isoforma a, b, c, d, e, f, g o h, que tiene la secuencia dada en la SEQ ID Nº 9, 10, 11, 12, 13, 14, 15, o 16 respectivamente; o ii. una secuencia que tiene al menos 95% de identidad de secuencia con respecto a las SEQ ID Nº 9, 10, 11, 12, 13, 14, 15 o 16 y que mantiene la funcionalidad como STXBP1; o iii. una variante de origen natural que comprende, con referencia a la SEQ ID Nº 9, una o más mutaciones, como se observa en la Tabla 7. Reivindicación 6: Un vector vírico que comprende el constructo de ácido nucleico de acuerdo con una cualquiera de las reivindicaciones precedentes, caracterizado porque el vector vírico comprende, además, una repetición terminal invertida (ITR) en el flanco 5’ y/o 3’ de dicho constructo de ácido nucleico. Reivindicación 9: Una partícula vírica que comprende un constructo de ácido nucleico de acuerdo con una cualquiera de las reivindicaciones 1 a 5, o un vector vírico de acuerdo con una cualquiera de las reivindicaciones 6 a 8.
ARP220102900A 2021-10-28 2022-10-26 Constructos de ácido nucleico, vectores víricos y partículas víricas AR127455A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163263175P 2021-10-28 2021-10-28

Publications (1)

Publication Number Publication Date
AR127455A1 true AR127455A1 (es) 2024-01-24

Family

ID=84362196

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102900A AR127455A1 (es) 2021-10-28 2022-10-26 Constructos de ácido nucleico, vectores víricos y partículas víricas

Country Status (4)

Country Link
AR (1) AR127455A1 (es)
CA (1) CA3234666A1 (es)
TW (1) TW202325849A (es)
WO (1) WO2023073071A1 (es)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
WO2009084472A1 (ja) * 2007-12-28 2009-07-09 Public University Corporation Yokohama City University 新生児期～乳児期発症の難治性てんかんの検出方法
WO2010020642A1 (en) * 2008-08-20 2010-02-25 Brainco Biopharma, S.L. Stxbp1 as psychiatric biomarker in murine model system and their uses
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
TWI808079B (zh) * 2017-04-03 2023-07-11 美商編碼製藥公司 組織選擇性轉基因表現
CN114929869A (zh) * 2019-11-08 2022-08-19 科亚韦治疗公司 修饰的腺相关病毒载体及将其递送至中枢神经系统
EP4179098A1 (en) * 2020-07-08 2023-05-17 Baylor College Of Medicine Gene therapy for stxbp1 encephalopathy
WO2022214635A1 (en) * 2021-04-08 2022-10-13 Stichting Vu Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders

Also Published As

Publication number Publication date
WO2023073071A1 (en) 2023-05-04
TW202325849A (zh) 2023-07-01
CA3234666A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
PH12019500280A1 (en) Trimer stabilizing hiv envelope protein mutations
CY1122800T1 (el) Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων
ES2548030T3 (es) Moléculas con semividas prolongadas y usos de las mismas
CO2018005306A2 (es) Variantes del factor viii reducido con cpg, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasia
EP4272765A3 (en) Adeno-associated virus (aav) clade f vector and uses therefor
AR125394A2 (es) Métodos y composiciones para la expresión génica en plantas
AU2018298422A1 (en) Novel nucleic acid molecules
MX2019006467A (es) Composiciones y métodos para mejorar la expresión génica.
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
AR114339A1 (es) Plataforma de presentación, productos y métodos con endosporas basadas en paenibacillus
AR057884A1 (es) Plantas con caracteristicas de crecimiento mejoradas y un metodo para desarrollarlas
PE20200722A1 (es) Metodos de terapia genica del factor viii (fviii)
MX2022005252A (es) Composiciones de escherichia coli y metodos de las mismas.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
PH12020500025A1 (en) Trimer stabilizing hiv envelope protein mutations
BR112021017603A2 (pt) Vírus adenoassociado (aav) mutante tendo propriedade de direcionamento para o cérebro
AR127455A1 (es) Constructos de ácido nucleico, vectores víricos y partículas víricas
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
AR061393A1 (es) Componentes transportadores de nitrato
BR112022006842A2 (pt) Construtos de igf2 variante
NO20085201L (no) Rekombinante novirhabdoviruser og deres anvendelse
EA202090326A1 (ru) Стабилизирующие тример мутации белка оболочки hiv
CO2023015564A2 (es) Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv
BR112023004874A2 (pt) Construções de ácido nucléico, vetores virais e partículas virais